NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of innovative adult stem cell technologies for debilitating neurodegenerative disorders, today announced that BrainStorm’s Phase I/II clinical trial for amyotrophic lateral sclerosis (ALS) at the Hadassah Medical Center, was featured on the Israeli Radio popular Morning News (Yoman Haboker). BrainStorm’s NurOwn™ autologous adult stem cell therapy is in clinical trial for ALS, often referred to as Lou Gehrig's Disease, a devastating neurodegenerative disease.
